Pharmaceutical

Gilead Named to Dow Jones Sustainability World Index for Third Consecutive Year

- Gilead Also Included on the Dow Jones Sustainability North America Index; Rankings Reflect Gilead's Ongoing Commitment to Corporate Responsibility…

3 months ago

Harrow Partners with Leading Healthcare Market Access Technology Platforms

Agreements Support the Upcoming Launch of VEVYE®NASHVILLE, Tenn.--(BUSINESS WIRE)--$HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that…

3 months ago

Introducing PillSafe(R), the New ‘Smart’ Pill Bottle for Prescription Medication

PillSafe® protects the patient with a patented, innovative pill distribution control system that improves dosage safety, prevents prescription drug misuse,…

3 months ago

Protagonist Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

NEWARK, CA / ACCESSWIRE / January 3, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh…

3 months ago

Assertio Holdings, Inc. Announces Leadership Transition

Dan Peisert Stepping Down as CEO Board member Heather Mason Appointed Interim CEO LAKE FOREST, Ill., Jan. 03, 2024 (GLOBE…

3 months ago

Xenon Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

VANCOUVER, British Columbia, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that…

3 months ago

NightHawk Biosciences Commences Work on Multi-Million-Dollar Development and Manufacturing Agreement For a Leading National University

Scorpius subsidiary to manufacture novel biologic targeting substance use disorderDURHAM, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE…

3 months ago

Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment

Additional Ewing Sarcoma Patient in Company’s Phase 1/2 Sarcoma Trial Achieves Partial Response; Objective Response Rate Among First-Relapse Ewing Patients…

3 months ago

CRISPR Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

ZUG, Switzerland and BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating…

3 months ago

AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer’s and Parkinson diseases

AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases ABATE Phase 1b/2 AD…

3 months ago